LGL Leukemia Program
LGL Leukemia Program
Large Granular Lymphocyte (LGL) Leukemia is a rare form of blood cancer, with less than 1,000 new cases diagnosed in the United States each year. Because it is so rare, physicians often overlook or misdiagnose the disease. UVA Cancer Center specializes in the diagnosis and treatment of LGL Leukemia, offering the latest in research-based care and knowledge of advanced therapies for patients with the disease.
Watch an LGL leukemia patient and his wife as they talk about their experience from diagnosis through treatment in this . To make an appointment please call 434.924.9333
History of LGL Leukemia
More than 30 years ago, UVA Cancer Center Director Thomas P. Loughran, Jr., MD discovered LGL Leukemia, a cancer of the blood, while working at Fred Hutchinson Cancer Research Center in Seattle, Washington. Since then, Dr. Loughran has dedicated his research and clinical focus to understanding this rare disease and working on new ways to treat it. As the renowned expert in LGL Leukemia, Dr. Loughran sees patients from around the world.
LGL Leukemia Clinic
UVA Cancer Center's LGL Leukemia Program includes a weekly clinic where Dr. Loughran offers new patient consultations and follow up appointments with existing patients. All patients undergo laboratory testing in the clinic to confirm their diagnosis or monitor their treatment progress. The clinic is held at the Emily Couric Clinical Cancer Center, where patients have access to state of the art facilities, supportive care and ancillary services. UVA Cancer Center is one of 69 NCI designated cancer centers.
Multimedia: Learn more about UVA Cancer Center and our multidisciplinary team approach to cancer treatment.
Resources for Patients:
For patients who are seeking expert care for LGL leukemia but do not live near Charlottesville, Virginia, there is an established by a generous donor to offset the costs of getting to UVA Cancer Center. If you would like to apply for assistance, please complete the programLGL Travel Fund Financial Assistance Application Form (PDF) and submit it electronically.
LGL Leukemia Registry
UVA is home to the LGL Leukemia Registry, which is the only national registry that collects, manages and analyzes information on people with LGL leukemia. It also maintains a bank of tissue and blood samples from LGL patients. The registry is key to research efforts for LGL leukemia and is maintained at UVA under the direction of Dr. Loughran.
How the Registry Supports Research Efforts
To understand a particular disease process, researchers rely on tissue and blood samples from patients for accurate details and information they wouldn't otherwise be able to obtain. As such, patient samples collected through the LGL Leukemia Registry are critical to the LGL leukemia research program at UVA.
Blood samples are processed immediately upon arrival into serum (the non-cellular liquid component of blood) and cells, with further separation of the cells into genetic (DNA and RNA) or structural (proteins or lipids) components. Researchers use the specimens for experimental analyses such as testing sensitivity to new or established drugs, discovery of genetic changes in leukemic cells and identification of any traits that support LGL leukemia cell survival.
Learn more or participate in the registry and help researchers further their knowledge of LGL leukemia and how to treat it.
The NIH is conducting a clinical trial for patients with T-Cell LGL Leukemia using the drug Alemtuzumab (Campath). Learn more about the clinical trial and eligibility requirements.